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Hepatocellular carcinoma (HCC) is one of the most frequent
human cancers worldwide, and it carries a very poor prognosis
(Whelan et al, 1993). Although genetic changes underlying the
development and progression of HCC are poorly understood, there
exist some well-known predisposing factors such as persistent
hepatitis due to viral infection and exposure to mycotoxins
(Rensburg et al, 1985; Nalpas et al, 1991; Tanaka et al, 1991). In
fact, most of HCC are associated with a background of chronic
liver disease (chronic viral hepatitis or cirrhosis). Both activation
of cellular oncogenes and inactivation of tumour suppressor genes
have been implicated in previous studies (Rogler et al, 1992; Tabor
et al, 1994; Di Bisceglie et al, 1997; Nishida et al, 1997).
Cellular proto-oncogenes may be activated through insertion of
a viral genome, a process similar to integration of retrovirus; in
a few cases, mutagenesis resulting from integration of hepatitis B
virus (HBV) into cellular genes has appeared to be linked to hepa-
tocarcinogenesis (Wang et al, 1990). However, since most HCCs
accompanied by infection with HBV contain viral DNA integrated
in the genome, this mechanism, as well as oncogene activation,
has been proposed as a general contributor to the development of
hepatocellular carcinoma (Simon and Carr, 1995). By contrast, to
our knowledge hepatitis C virus (HCV) is never integrated into the
genomes of hepatocytes (Fong et al, 1991; Kasai et al, 1996;
Di Bisceglie et al, 1997). The carcinogenic mechanisms of both
viruses are still under intensive investigations.
Among the tumour suppressors most frequently inactivated in
HCCs is the p53 gene, mutated in 25–60% of these tumours (Oda
et al, 1992; Fujimoto et al, 1994). Losses of heterozygosity (LOH)
at chromosomes 1p, 4q, 5q, 8p, 11p, 13q, 16q, 17p and/or 22q are
common in HCC (Tsuda et al, 1990; Zhang et al, 1990; Fujimori
et al, 1991; Simon et al, 1991). Classical cytogenetic studies have
detected losses of the same chromosome arms in HCCs (Fourel
et al, 1994). Therefore, some putative tumour suppressor genes at
these loci may be involved in the development and progression of
HCC.
Comparative genomic hybridization (CGH) is a molecular cyto-
genetic method that makes it possible to survey the entire genome
for gains and losses of DNA sequences (Kallioniemi et al, 1992,
1994). The utility of CGH is based on the concept that regions with
increased copy number reveal chromosomal sites that may contain
dominant oncogenes, whereas regions with decreased copy number
may be loci of putative tumour suppressor genes (Kallioniemi et al,
1992, 1994). CGH reliably screens the entire human genome, and
therefore allows detection of any chromosomal sites that are likely
to contain genes with an important role in tumour development
(Ariyama et al, 1998; Sakakura et al, 1999).
In the study reported here, CGH analysis was performed in 35
cases of HCC with HCV infection (hereafter, HCV-HCC) in order
to identify those regions that contain potential oncogenes or
tumour suppressor genes responsible for hepatocellular carcino-
genesis.
MATERIALS AND METHODS
Primary tumour specimens
The material consisted of 35 primary human hepatocellular carci-
nomas with HCV infection. The clinical stage distribution of these
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cases was as follows: stage 1, three cases; stage 2, 11 cases; stage
3, 14 cases; stage 4, seven cases. High molecular weight tumour
DNA was isolated from homogenized tumour specimens using
standard protocols. Normal human male DNA was also isolated
from the peripheral blood of a male volunteer as using a reference
DNA for CGH.
CGH and digital image analysis
CGH was performed using directly fluorochrome-conjugated
DNA as described elsewhere (Ariyama et al, 1998; Sakakura et al,
1999). Three single-colour images (DAPI, Spectrum green and
Texas red fluorescence) were collected from each metaphase
spread using an epifluorescence microscope (Nikon, Tokyo,
Japan), a cooled charge-coupled device (CCD) camera
(Hamamatsu Photonics, Hamamatsu, Japan), and analysed using a
digital image analysis system, The Power Gene, Mac Probe (PSI,
Perceptive Scientific Instrument). Chromosomal regions where
the mean ratio fell below 0.8 were therefore considered to reflect
losses of DNA (underrepresentation), whereas regions where the
mean ratio exceeded 1.2 were considered gained (overrepresenta-
tion) in the tumour genome. Overrepresentations were considered
to be high-level amplifications when the fluorescence ratio
exceeded 1.5 (Sakakura et al, 1999). Heterochromatic regions near
the centromeres and the entire Y chromosome were excluded from
analysis.
RESULTS
An overview of genetic changes in 35 HCCs is shown in Figure 1
and listed in Table 1. Thirty-two tumours (92%) showed DNA
sequence copy number changes, which was significantly higher
than previous cytogenetic studies had indicated (Lowichik et al,
1996). This reflects the power of CGH in revealing aberrations
across the genome in uncultured cells. Three tumours had no copy
number changes. None of six normal liver tissues showed any
gains or losses of DNA sequence copy number (data not shown).
Losses in HCC predominated over gains with a ratio of 1:1.2. On
average, there were 7.6 (range 0–12) aberrations per primary
tumour: 3.4 gains (range 0–6) and 4.2 losses (range 0–7).
The most common copy number changes were losses at
1p34–36 (13/35; 37%), 4q12–21 (17/35; 48%), 5q13–21 (12/35;
35%), 6q13–16 (8/35; 23%), 8p21–23 (10/35; 28%), 13q (7/35;
20%), 16q (12/35; 33%) and 17p13 (13/35; 37%). Gains were seen
in 1q (16/35; 46%), 6p (7/35; 20%), 8q21–24 (11/35; 31%) and
17q (15/35; 43%). Minimal overlapping regions of common DNA
copy number changes in these HCCs, and their relationship to
known locations of oncogenes, tumour suppressor genes, or
Table 1 DNA copy number changes in each of 35 hepatocellular carcinomas
Sample no. Gain Loss Histology, stage
1 – 12q, X Ed1, T2N0M0 Stage 2
2 1q, 7q31, 12q, 14q12 1p Ed3, T3N0M0 Stage 3
3 14q12, 8q,9q,16p,19p,20 1p,4q,5q,8p,10,11q,13q Ed3, T1N0M0 Stage 1
4 8q 1p31–36, 4q, 6q, 8p, Ed2, T2NXM0 Stage 2
5 1q,3,6,17q 4,11,12p,13q,14q,15q,18p Ed3, T3N0M0 Stage 3
6 1q,5p, 8q 4q,5,8p,14q,17p,19 Ed2, T2N0M0 Stage 2
7 – – Ed2, T3N0M0 Stage 3
8 1q, 7,15q,16p 1p,4q,5q,13q,16q Ed2, T4N0M0 Stage 4a
9 1q,8q,17q, 20 2,3,4,5q,6q 14–26,11 Ed2, T2N0M0 Stage 2
10 1q,8q,10,14q 1p,7q,10q,16,17,18q,19,20,21q Ed2, T1N0M0 Stage 1
11 3,10q,12,17q,20 1p34–36,3p12–13,4q,7,16,17p13 Ed2, T4N0M0 Stage 4a
12 1q,3, 4p,5q,6,16,17q 10,15q,21q,Xp,Xq12–21 Ed4, T3N0M0 Stage 3
13 3,17q,Xq 5p,5q11–32,15q,18 Ed2, T1N0M0 Stage 1
14 7,8q,17q,19q,20,22q 8p,12p Ed3, T4NXM0 Stage 4a
15 1q,6p,7p14–22,14q,15q,17q,21q 3p22–26,4q,6q,7p,12q Ed2, T2N0M0 Stage 2
16 1q,1q,8q,15q 9q,12q24,16,17,19,20,21q Ed2, T2N0M0 Stage 2
17 15q 1p Ed2, T3N0M0 Stage 3
18 1q,2,8q,11,12,14q,17q,18,19 1p,4q Ed3, T3N0M0 Stage 3
19 1q,3,4p,11p,17,19q,21q 1p,4q,6q,9q22–24,16,17p13,18,19 Ed4, T3N0M0 Stage 3
20 – 17p Ed2, T2N0M0 Stage 2
21 1q,2,3,11q13,17q,X, 4q12–31,9q31–34,17p,19,21q,22q Ed1, T3N0M0 Stage 3
22 2,4,11p,13q,15q,19 5q14–23,6q Ed2, T3N0M0 Stage 3
23 6p,17q, 6q,17p,8p21–23 Ed2, T3N0M0 Stage 3
24 1q,8q,10p,17q,20,21q 1p,2,4,5,8q,9p22–24,13q,16q,17p,X Ed3, T2N0M0 Stage 2
25 2,6,16p,X 1p,4q,13q,16q,18q Ed2, T3N0M0 Stage 3
26 1q,2p,6p,8q,17,20,X 1p,5q,6q,16,18,20 Ed2, T4N0M0 Stage 4a
27 17q12 17p,19,22q Ed4, T4N0M0 Stage 4a
28 – – Ed2, T2N0M0 Stage 2
29 – – Ed2, T3N0M0 Stage 3
30 8q,18,19q,X 1q22–32,2q,4,6q,13q,17,19 Ed2, T4N0M0 Stage 4a
31 1q,4p 4q,5q,8p,16,19,22q Ed3, T2N0M0 Stage 2
32 2p,17,8q21–24 5q,6,8p,17p,21q Ed2, T3N0M0 Stage 3
33 11p,16p,17q,19p,20 4,8p,9p,16q,19,21q Ed3, T4N0M0 Stage 4a
34 1q,11p,15q, 21q 5q, 8p, 9,16q,17p13,19 Ed2, T3N0M0 Stage 3
35 6p,9q,11, 12q14–22 1p, 4, 5q, 8p21–23,12p,13q,16q,17p Ed3, T2N0M0 Stage 2
*The regions of high level gain are written in bold. TNM classification of UICC was used for staging system. Edmondson classification was used for histological
classification.2036 C Sakakura et al
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adhesion molecule genes are listed in Table 2. High level gains
indicative of amplified genes were found in 7q31 (1/35; 3%),
11q13 (1/35; 3%), 14q12 (2/35; 6%) and 17q12 (1/35; 3%).
Figure 2A shows the typical two-colour image among our panel
of CGH. The DAPI-stained image of the same metaphase from
which the chromosomes were identified is shown in Figure 2B. Its
copy number profile is shown in Figure 2C. DNA gains are evident
on chromosomes 1q, 5p and 8q. Losses on chromosomes 4, 5q, 8p,
14q 17p and 19 are also readily apparent.
DISCUSSION
Screening for HBV prior to blood transfusion has decreased the
incidence of HCC with HBV infection in Japan, and more than
80% of HCC in Japan is now associated with HCV infection
(Tanaka et al, 1991; The Liver Cancer Study Group in Japan,
1994; Takano et al, 1995). The role of HCV-infection in the aeti-
ology of HCC and cirrhosis now seems to be more important than
chronic hepatitis B infection. Although HBV is randomly inte-
grated into the genome of hepatocytes in more than 90% of HCC
with HBV infection (HBV-HCC) (Tokino et al, 1987; Tabor et al,
1994), HCV does not integrate into the genome as far as we know
(Fong et al, 1991; Di Biscegli et al, 1997). The mechanism by
which HCV contributes to development of HCC is unclear.
However, as patients with HCV infection tend to be older and
show more severe liver cirrhosis than patients with HBV-HCC, not
only the background but also the mechanism involved in initiation
of carcinogenesis may be different for the two viruses.
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Figure 1 Schematic view of DNA copy number changes in 35 human hepatocellular carcinomas, with CGH data plotted in ideogram form. The 22 autosomal
chromosomes and the X chromosome are represented by ideograms showing G-banding patterns, oriented with p-arms at the top. Each region of decrease in
DNA is represented as a thin solid line to the left of and parallel to the chromosomal region where it occurs, as judged by computerized green-to-red profiles
(see Materials and Methods). Each copy number increase is likewise represented as a thin solid line, to the right of the region where it occurs. Regions of
frequent copy number change have multiple parallel lines beside them, and gene amplifications are indicated by open rectangles. The data are summarized in
Tables 1 and 2
Table 2 Minimal overlapping regions of common DNA copy number
changes in hepatocellular carcinoma
DNA
copy number Locus Frequency Putative target genes
Increase 1q 46% (16/35) PTPRC, ARG
6p 20% (7/35) PIM1
8q21–24 31% (11/35) MYC
17q 43% (15/35) ERBB2
High level gain (amplification)
7q31 3% (1/35) MET
11q13 3% (1/35) HST1/INT2
14q12 6% (2/35)
17q12 3% (1/35) ERBB2
Decrease 1p34–36 37% (13/35) TP73
4q12–21 48% (17/35)
5q13–21 35% (12/35) APC
6q13–16 23% (8/35)
8p21–23 28% (10/35)
13q 20% (7/35) RB
16q 33% (12/35) E-Cadherin (CDH1)
17q13 37% (13/35) TP53Chromosomal abnormalities in HCC with HCV infection 2037
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Our CGH analysis of 35 HCV-HCCs showed frequent imbal-
ances on chromosomes 1, 4q, 5q, 6, 8, 16q and 17. These data are
concordant with the results recently reported for HBV-HCCs
(Marchio et al, 1997); a similar cohort of oncogenes and suppressor
genes at these loci may be involved in the development and
progression of both HBV- and HCV-related HCC. Our CGH results
also agree with those of investigators who found no correlation
between LOH in specific chromosomal regions and chronic infec-
tions with hepatitis B or C (Konishi et al, 1993; Nagai et al, 1997).
LOH analyses have revealed that allelic loss of 4q is a frequent
change in early-stage HCCs (Fujimoto et al, 1991; Nagai et al,
1996), and this chromosomal region is thought to harbour one or
more tumour suppressor genes (Buetow et al, 1989; Yeh et al,
1996). To our knowledge, underrepresentation of this locus, as
revealed by CGH, has never been reported in other types of
cancers, so HCC-specific tumour suppressor genes may exist
there. Another group of investigators reports that loss of 4q21–22
region occurred preferentially in well-differentiated HCC and
they considered this a secondary event that increased the
aggressiveness of established cancer (Kuroki et al, 1995). It has
also been reported that loss of 4q is related to increased serum AFP
(alpha-fetoprotein) levels (Yeh et al, 1996). In our CGH analysis
of HCCs, the most commonly recurrent loss (4q) was observed in
45% of tumour specimens, the smallest region of overlap being
4q12–21. This result supported the view that chromosome 4q,
particularly 4q12–21, harbours tumour suppressor activity that is
lost during tumorigenesis in HCV-HCC.
We have explored possible correlations between clinicopatho-
logical characteristics and copy number changes in the tumours of
our panel. The first objective of the statistical analysis was to
examine relationship of total copy number changes with cancer
stage. Information obtained from the univariate analysis (log-rank
test) was applied to total copy number changes with cancer stage
using the Cox model of proportional hazards, but we have found
no relation between two factors. In the same way, we tried to
analyse the relationship between copy number changes on specific
chromosomes and tumour stage, but it could not be evaluated
statistically because too few early-stage tumours (three cases)
were among the total. Changes on 1p, 1q and 4q were detected in
the HCCs classified as stage T1 (< 2 cm in diameter) with almost
same frequency as more advanced HCCs.
The recurrently underrepresented sites observed in this CGH
study, i.e. 1p, 5p, 16q and 17p, have also been reported to be
common regions of allelic loss in HCC. Each of these segments is a
known or suspected site of tumour suppressor genes, e.g. p53 at
17p13, APC at 5q21, RB at 13q14, CDH1 at 16q21–24. Frequent
genetic alterations in the distal region of chromosome 1p in HCCs
suggest loss of this region is critical for initial hepatocarcinogenesis
(Yeh et al, 1994). Recently p73, whose function is related to p53, was
isolated from 1p36 (Kaghad et al, 1997). Unidentified suppressor
genes associated with HCC appear to present on chromosome 8p
(Emi et al, 1993; Fujiwara et al, 1994). The underrepresentation of
17p (45%) in our study is explained by loss of the p53 gene
(17p13.1), a frequent feature of HCC (Fujimoto et al, 1994).
Over-representation of chromosome arm 1q was the most
frequent feature in our series of tumours that shows copy-number
increases; 16 of them exhibited gain involving 1q. Moreover,
increased copy number at 1q has also been reported in a variety of
other tumours including breast, gastric and neuroblastoma, all
related to poor prognosis and sometimes to metastases (Borg
et al, 1992; Tahara, 1995). Chromosome 1q contains the Abelson-
related oncogene (ARG; Kruh et al, 1990) and the protein tyrosine
phosphatase receptor type c polypeptide gene (PTPRC;
Schaapveld et al, 1995), both of which are associated with cell
growth and proliferation.
Overrepresentations of 17q and 8q, the second and third most
common gains of DNA observed in this series, included amplifica-
tion of 17q12 in one tumour. A potentially relevant gene on 17q12,
ERBB2, encodes an EGF-like growth factor receptor (Kameda
et al, 1990); another, whose product may contribute to control of
cell proliferation and malignant transformation, is MYC; a gene
that is over-expressed in most HCCs (Moroy et al, 1986). Gains at
6p (20% in our study) have not been previously described in HCC,
although tumour-specific copy number increases at 6p have been
reported in retinoblastomas and osteosarcomas (Cano et al, 1994;
Forus et al, 1995), where PIM1 may be one of the target genes.
CGH is particularly powerful in revealing discrete amplified
loci. In our analysis, we detected four distinct amplification sites;
7q31, 11q13, 14q12 and 17q12. Putative target genes on 7q31,
11q13 and 17q12 are MET, HST/INT2 and ERBB2, respectively,
but amplification on 14q12 has never been reported in any other
type of cancer. Therefore a novel gene whose overexpression is
specific for HCC may exist there; amplification of this locus has
A
B
Figure 2 (A) Typical two-colour image of CGH in hepatocellular carcinoma.
Differentially labelled tumour (green) and normal (red) DNAs were hybridized
onto a normal human metaphase spread (46, XY). Chromosomal regions
that are overrepresented in the tumour appear green, regions that are under-
represented appear red and unrelated regions appear yellow. Chromosomes
showing copy number changes are numbered at their q ends; DNA gains are
evident on chromosomes 1q, 5p and 8q. Losses on chromosomes 4, 5q, 8p,
14q and 17p are also readily apparent. (B) DAPI-stained image of the same
metaphase cell shown in panel A. DAPI banding patterns were used for
chromosome identification.2038 C Sakakura et al
British Journal of Cancer (1999) 80(12), 2034–2039 © 1999 Cancer Research Campaign
also been detected in HBV-HCC, along with amplifications of
11q13, 12p11 and 19q13 (Marchio et al, 1997). Amplifications we
observed at 7q31, 11q13 and 17q12 have also been reported in
other types of cancers (Tahara et al, 1994; Knuutila et al, 1998).
In summary, the recurrent copy number decreases we identified
by CGH analysis support previous data on allelic loss in HCCs,
and further implicate those sites as locations of tumour suppressor
genes. Our study reveals that the pattern of chromosomal aberra-
tions in HCC with HCV infection, although highly complex and
involving virtually every chromosome, is clearly non-random and
similar to CGH pattern of HCCs with HBV infection. In addition,
many of the overrepresented chromosome segments observed in
HCC are sites of known oncogene/growth-regulatory genes
already implicated in tumorigenesis. Other overrepresented
regions could be sites of novel amplified DNA sequences which
may provide growth advantages in these aggressive neoplasms.
ACKNOWLEDGEMENTS
This work was supported by grants-in-aid from the Ministry of
Health and Welfare; the Ministry of Education, Science, Sports
and Culture; the Organization for Pharmaceutical Safety and
Research, Japan; a grant from Cell Fate Modulation Research
Unit; and Research Grant of the Princess Takamatsu Cancer
Research Fund.
REFERENCES
Ariyama Y, Fukuda Y, Okuno Y, Seto M, Date K, Abe T, Nakamura Y and Inazawa J
(1998) Amplification on double-minute chromosomes and partial-tandem
duplication of the MLL gene in leukemic cells of a patient with acute
myelogenous leukemia. Genes Chromosomes Cancer 23: 267–272
Borg A, Zhang QX, Olsson H and Wenngren E (1992) Chromosome 1 alterations in
breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases
and poor prognosis. Genes Chromosomes Cancer 5: 311–320
Buetow KH, Murray JC, Israel JL, London WT, Smith M, Kew M, Blanquet V,
Brechot C, Redeker A and Govindarajah S (1989) Loss of heterozygosity
suggests tumor suppressor gene responsible for primary hepatocellular
carcinoma. Proc Natl Acad Sci USA 86: 8852–8856
Cano J, Oliveros O and Yunis E (1994) Phenotype of variants malignancy, additional
copies of 6p in retinoblastoma. Cancer Genet Cytogenet 76: 112–115
Di Biscegli AM (1997) Hepatitis C and hepatocellular carcinoma. Hepatology 26:
34S–38S
Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi S, Koike M, Miyaki M, Monden
M and Nakamura Y (1993) Allelic loss at chromosome band 8p21.3–p22 is
associated with progression of hepatocellular carcinoma. Genes Chromosomes
Cancer 7: 152–157
Fong TL, Shindo M, Feinstone SM, Hoofnagle JH and Di Bisceglie AM (1991)
Detection of replicative intermediates of hepatitis C viral RNA in liver and
serum of patients with chronic hepatitis C. J Clin Invest 88: 1058–1060
Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O and Geurts Van Kessel A
(1995) Comparative genomic hybridization analysis of human sarcomas: II.
Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes
Chromosomes Cancer 14: 15–21
Fourel G (1994) Genetic and epigenetic alterations of gene expression in the course
of hepatocarcinogenesis. In: Liver Gene Expression, Tronche F and Moshe Y
(eds), pp. 298–343. R.G. Landes: Austin, TX
1 n=9 2 n=8 3 n=8 4 n=9 5 n=8
67 8 9 10 11 12 n=8 n=8 n=8 n=8 n=8 n=9 n=8
13 n=8 14 n=8 15 n=7 16 n=8 17 n=8 18 n=8
19 n=8 20 n=8 21 n=7 22 n=8 X n=7 Y
n=4
Figure 2C Computer-generated mean and standard deviation fluorescence ratio profiles for several metaphases from the hepatocellular carcinoma (Sample
No 6). The central horizontal dashed line represents a green-to-red fluorescence ratio of 1 (no copy number change)Chromosomal abnormalities in HCC with HCV infection 2039
British Journal of Cancer (1999) 80(12), 2034–2039 © 1999 Cancer Research Campaign
Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, Mitsunobu M,
Ishikawa T, Nakagawa H, Hayada H, Yagura M, Matsubara K and Nakamura Y
(1991) Allotype study of primary hepatocellular carcinoma. Cancer Res 51:
89–93
Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP and Thorgeirsson SS (1994)
Alteration of tumor suppressor genes and allelic losses in human hepatocellular
carcinomas in China. Cancer Res 54: 281–285
Fujiwara Y, Ohata H, Emi M, Okui K, Koyama K, Tsuchiya E, Nakajima T, Monden
M, Mori T, Kurimasa A, Oshimura M and Nakamura Y (1994) A 3-Mb
physical map of the chromosome region 8p21.3–p22, including a 600-kb
region commonly deleted in human hepatocellular carcinoma, colorectal
cancer, and non-small cell lung cancer. Genes Chromosomes Cancer 10: 7–14
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon
P, Lelias JM, Dumont X, Ferrara P, McKeon, F and Caput D (1997)
Monoallelically expressed gene related to p53 at 1p36, a region frequently
deleted in neuroblastoma and other human cancers. Cell 90: 809–819
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F and
Pinkel D (1992) Comparative genomic hybridization for molecular cytogenetic
analysis of solid tumors. Science 258: 818–820
Kallioniemi A, Kallioniemi O-P, Piper J, Tanner M, Stokke T, Chen L, Smith HS,
Pinkel D, Gray JW and Waldman FM (1994) Detection and mapping of
amplified DNA sequences in breast cancer by comparative genomic
hybridization. Proc Natl Acad Sci USA 91: 2156–2160
Kameda T, Yasui W, Yoshida K, Tsujino T, Nakayama H, Ito M, Ito H and Tahara E
(1990) Expression of ERBB2 in human gastric carcinomas; relationship
between p185ERBB2 and the gene amplification. Cancer Res 15: 8002–8009
Kasai Y, Takeda S and Takagi H (1996) Pathogenesis of hepatocellular carcinoma: a
review from the viewpoint of molecular analysis. Semin Surg Oncol 12:
155–159
Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska
J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM,
Vidgren V and Zhu Y (1998) DNA copy number amplifications in human
neoplasms: review of comparative genomic hybridization studies. Am J Pathol
152: 1107–1123
Kruh GD, Perego R, Miki T and Aaronson SA (1990) The complete coding
sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases.
Proc Natl Acad Sci USA 87: 5802–5806
Kuroki T, Fujiwara Y, Tsuchiya E, Nakamori S, Imaoka S, Kanematsu T and
Nakamura Y (1995) Accumulation of genetic changes during development of
and progression of hepatocellular carcinoma: Loss of heterozygosity on
chromosome arm 1p occurs at early stage of hepatocarcinogenesis. Genes
Chromosomes Cancer 13: 163–167
Lowichik A, Schneider NR, Tonk V, Ansari MQ and Timmons CF (1996) Report of
a complex karyotype in recurrent metastatic fibrolamellar hepatocellular
carcinoma and a review of hepatocellular carcinoma cytogenetics. Cancer
Genet Cytogenet 88: 170–174
Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A and Dejean A
(1997) Recurrent chromosomal abnormalities in hepatocellular carcinoma
detected by comparative genomic hybridization. Genes Chromosomes Cancer
18: 59–65
Moroy T, Marchio A, Etiemble J, Trepo C, Tiollais P and Buendia MA (1986)
Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma
of hepatitis virus infected woodchucks. Nature 324: 276–279
Nagai H, Pineau P, Tiollais P, Buendia MA and Dejean A (1997) Comprehensive
allelotyping of human hepatocellular carcinoma. Oncogene 14: 2927–2933
Nalpas B, Driss F, Pol S, Hamelin B, Housset C, Brechot C and Berthelot P (1991)
Association between HCV and HBV infection in hepatocellular carcinoma and
alcoholic liver disease. J Hepatol 12: 70–74
Nishida N, Fukuda Y, Ishizaki K and Nakao K (1997) Alteration of cell cycle-related
genes in hepatocarcinogenesis. Histol Histopathol 12: 1019–1025
Oda T, Tsuda H, Scarpa A, Sakamoto M and Hirahashi S (1992) P53 gene mutation
spectrum in hepatocellular carcinoma. Cancer Res 52: 6358–6364
Rogler CE and Chisari FV (1992) Cellular and molecular mechanisms of
hepatocarcinogenesis. Semin Liver Dis 12: 265–278
Sakakura C, Mori T, Sakabe T, Ariyama Y, Shinomiya T, Date K, Hagiwara A,
Yamaguchi T, Takahashi T, Nakamura Y, Abe T and Inazawa J (1999)  Gains,
losses, and amplifications of genomic materials in primary gastric cancers
analyzed by comparative genomic hybridization. Genes Chromosomes Cancer
24: 299–305
Schaapveld RQ, Van Den Maagdenberg AM, Schepens JT, Weghuis DO, Geurts Van
Kessel A, Wieringa B and Hendriks WJ (1995) The mouse gene Ptprf encoding
the leukocyte common antigen-related molecule LAR: cloning,
characterization, and chromosomal localization. Genomics 27: 124–130
Simon D, Knowles BB and Weith A (1991) Abnormalities of chromosome 1 and
loss of heterozygosity of 1p in primary hepatomas. Oncogene 6: 765–770
Simon D and Carr BI (1995) Integration of hepatitis B virus and alteration of the
1p36 region found in cancerous tissue of primary hepatocellular carcinoma
with viral replication evidenced only in noncancerous, cirrhotic tissue.
Hepatology 22: 1393–1398
Tabor E (1994) Tumor suppressor genes, growth factor genes, and oncogenes in
hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 42: 357–365
Tahara E (1995) Molecular biology of gastric cancer. World J Surg 19: 484–488
Takano S, Yokosuka O, Imazeki F, Tagawa M and Omata M (1995) Incidence of
hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of
251 patients. Hepatology 21: 650–655
Tanaka K, Hirohata T, Koga S, Sugimachi K, Kanematsu T, Ohryohji F, Nawata H,
Ishibashi H, Maeda Y, Kiyokawa H, Tokunaga K, Irita Y, Takeshita S, Arase Y
and Nishino N (1991) Hepatitis C and hepatitis B in the etiology of
hepatocellular carcinoma in the Japanese population. Cancer Res 51: 2842–2847
The Liver Cancer Study Group of Japan (1994) Predictive factors for long term
prognosis after partial hepatectomy for patients with hepatocellular carcinoma
in Japan. Cancer 74: 2772–2780
Tokino T, Fukushige S, Nakamura T, Nagaya T, Murotsu T, Shiga K, Aoki N and
Matsubara K (1987) Chromosomal translocation and inverted duplication
associated with integrated hepatitis B virus DNA in hepatocellular carcinomas.
J Virol 61: 3848–3854
Tsuda H, Zhang W, Shimosato Y, Yokota J, Terada M, Sugimura T, Miyamura T and
Hirohashi S (1990) Allele loss on chromosome 16 associated with progression
of human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6791–6794
Van Rensburg SJ, Cook-Mozafarri P, Van Schlkwyk DJ, Van Der Watt JJ, Vincent TJ
and Purchase IF (1985) Hepatocellular carcinoma and dietary aflatoxin in
Mozambique and Transkei. Br J Cancer 51: 713–726
Wang J, Chenivesse X, Henglein B and Brechot C (1990) Hepatitis B virus
integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343:
555–557
Whelan SL, Parkin DM and Masuyer E (eds) (1993) Trends in Cancer Incidence and
Mortality. IARC Scientific Publ., No. 102. IARC: Lyon
Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC and Chen DS (1994) Frequent
genetic alterations at the diastal region of chromosome 1p in human
hepatocellular carcinomas. Cancer Res 54: 4188–4192
Yeh SH, Chen PJ, Lai MY and Chen DS (1996) Allelic loss on chromosome 4q and
16q in hepatocellular carcinoma: association with elevated a-fetoprotein
production. Gastroenterology 110: 184–192
Zhang W, Hirohashi S, Tsuda H, Shimosato Y, Yokota J, Terada M and Sugimura T
(1990) Frequent loss of heterozygosity of chromosomes 16 and 4 in human
hepatocellular carcinoma. Jpn J Cancer Res 81: 108–111